Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls
Timo Vesikari, Nicholas Brodszki, Pierre Van Damme, et al.
The Pediatric Infectious Disease Journal (2015) Vol. 34, Iss. 9, pp. 992-998
Open Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
Marc Arbyn, Lan Xu, Cindy Simoens, et al.
Cochrane library (2018) Vol. 2020, Iss. 3
Open Access | Times Cited: 517
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women
Ole‐Erik Iversen, María J. Miranda, Àngels Ulied, et al.
JAMA (2016) Vol. 316, Iss. 22, pp. 2411-2411
Closed Access | Times Cited: 174
Human Papillomavirus Vaccines
Lauri E. Markowitz, John T. Schiller
The Journal of Infectious Diseases (2021) Vol. 224, Iss. Supplement_4, pp. S367-S378
Open Access | Times Cited: 108
An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy
Zahra Yousefi, Hamid Aria, Farhoodeh Ghaedrahmati, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 103
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males
Hanna Bergman, Brian S Buckley, Gemma Villanueva, et al.
Cochrane library (2019) Vol. 2019, Iss. 11
Open Access | Times Cited: 136
Escherichia coli-derived virus-like particles in vaccine development
Xiaofen Huang, Xin Wang, Jun Zhang, et al.
npj Vaccines (2017) Vol. 2, Iss. 1
Open Access | Times Cited: 130
Safety of Human Papillomavirus Vaccines: An Updated Review
Anastasia Phillips, Cyra Patel, Alexis Pillsbury, et al.
Drug Safety (2017) Vol. 41, Iss. 4, pp. 329-346
Closed Access | Times Cited: 113
HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection
Mary Roz Timbang, Michael W. Sim, Arnaud F. Bewley, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 7-8, pp. 1920-1928
Open Access | Times Cited: 110
Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials
Edson Duarte Moreira, Stan L. Block, Daron Ferris, et al.
PEDIATRICS (2016) Vol. 138, Iss. 2
Open Access | Times Cited: 105
HPV Vaccine: Updates and Highlights
Cristina Mendes de Oliveira, José Humberto Tavares Guerreiro Fregnani, Luisa L. Villa
Acta Cytologica (2019) Vol. 63, Iss. 2, pp. 159-168
Closed Access | Times Cited: 98
Virus Like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus
Himanshu Garg, Tugba Mehmetoglu-Gurbuz, Anjali Joshi
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 75
Rational design of a triple-type HPV53/56/66 vaccine with one preferable base particle incorporating two identified immunodominant sites
Ciying Qian, Jie Chen, Yurou Yang, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system
Yuying Liu, Dan Chen, Li Zhao, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 1
A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men
Pierre Van Damme, Chris J.L.M. Meijer, Dorothee Kieninger, et al.
Vaccine (2016) Vol. 34, Iss. 35, pp. 4205-4212
Open Access | Times Cited: 78
Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement
Debbie Saslow, Kimberly Andrews, Deana Manassaram‐Baptiste, et al.
CA A Cancer Journal for Clinicians (2016) Vol. 66, Iss. 5, pp. 375-385
Open Access | Times Cited: 73
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
Carlo Signorelli, Anna Odone, Veronica Ciorba, et al.
Epidemiology and Infection (2017) Vol. 145, Iss. 10, pp. 1962-1982
Open Access | Times Cited: 69
Overcoming barriers in HPV vaccination and screening programs
Alex Vorsters, Marc Arbyn, Marc Baay, et al.
Papillomavirus Research (2017) Vol. 4, pp. 45-53
Open Access | Times Cited: 67
Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis
Courtney A. Gidengil, Matthew Bidwell Goetz, Sydne J Newberry, et al.
Vaccine (2021) Vol. 39, Iss. 28, pp. 3696-3716
Open Access | Times Cited: 53
Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus
Maryam Dadar, Sandip Chakraborty, Kuldeep Dhama, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 57
9-Valent human papillomavirus vaccine: a review of the clinical development program
Alain Luxembourg, Erin Moeller
Expert Review of Vaccines (2017) Vol. 16, Iss. 11, pp. 1119-1139
Closed Access | Times Cited: 54
<p>Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus</p>
Zheng Quan Toh, Jennie Kosasih, Fiona M. Russell, et al.
Infection and Drug Resistance (2019) Vol. Volume 12, pp. 1951-1967
Open Access | Times Cited: 50
Autonomic dysfunction and HPV immunization: an overview
Svetlana Blitshteyn, Louise Brinth, Jeanne E. Hendrickson, et al.
Immunologic Research (2018) Vol. 66, Iss. 6, pp. 744-754
Closed Access | Times Cited: 49
Cost‐effectiveness of HPV‐based cervical screening based on first year results in the Netherlands: a modelling study
Erik E.L. Jansen, Steffie K. Naber, Clare A. Aitken, et al.
BJOG An International Journal of Obstetrics & Gynaecology (2020) Vol. 128, Iss. 3, pp. 573-582
Open Access | Times Cited: 42
Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review
Polona J. Maver, Mario Poljak
Vaccine (2017) Vol. 36, Iss. 36, pp. 5416-5423
Closed Access | Times Cited: 47
Update on the new 9-valent vaccine for human papillomavirus prevention.
David Yi Yang, Keyna Bracken
PubMed (2016) Vol. 62, Iss. 5, pp. 399-402
Closed Access | Times Cited: 45
Page 1 - Next Page

Scroll to top